1. Academic Validation
  2. BRCA2 prevents PARPi-mediated PARP1 retention to protect RAD51 filaments

BRCA2 prevents PARPi-mediated PARP1 retention to protect RAD51 filaments

  • Nature. 2025 Mar 26. doi: 10.1038/s41586-025-08749-x.
Sudipta Lahiri 1 2 George Hamilton 1 Gemma Moore 2 Liana Goehring 1 Tony T Huang 1 Ryan B Jensen 3 Eli Rothenberg 4
Affiliations

Affiliations

  • 1 Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, USA.
  • 2 Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
  • 3 Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA. ryan.jensen@yale.edu.
  • 4 Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, USA. eli.rothenberg@nyulangone.org.
Abstract

The tumour-suppressor protein BRCA2 has a central role in homology-directed DNA repair by enhancing the formation of RAD51 filaments on resected single-stranded DNA generated at double-stranded DNA breaks and stimulating RAD51 activity1,2. Individuals with BRCA2 mutations are predisposed to cancer; however, BRCA2-deficient tumours are often responsive to targeted therapy with PARP inhibitors (PARPi)3-6. The mechanism by which BRCA2 deficiency renders cells sensitive to PARPi but with minimal toxicity in cells heterozygous for BRCA2 mutations remains unclear. Here we identify a previously unknown role of BRCA2 that is directly linked to the effect of PARP1 inhibition. Using biochemical and single-molecule approaches, we demonstrate that PARPi-mediated PARP1 retention on a resected DNA substrate interferes with RAD51 filament stability and impairs RAD51-mediated DNA strand exchange. Full-length BRCA2 protects RAD51 filaments and counteracts the instability conferred by PARPi-mediated retention by preventing the binding of PARP1 to DNA. Extending these findings to a cellular context, we use quantitative single-molecule localization microscopy to show that BRCA2 prevents PARPi-induced PARP1 retention at homologous-recombination repair sites. By contrast, BRCA2-deficient cells exhibit increased PARP1 retention at these lesions in response to PARPi. These results provide mechanistic insights into the role of BRCA2 in maintaining RAD51 stability and protecting homologous-recombination repair sites by mitigating PARPi-mediated PARP1 retention.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-150147
    99.83%, BRCA2-RAD51 Interaction Inhibitor